Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).
Epithelial Ovarian Cancer
DRUG: Topotecan|DRUG: Belotecan
Objective response rate, approximately 21 days(every 1 Cycle)
Overall Survival, up to 4 years|Progression Free survival, up tp 4 years
A Phase â…¡b, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan (CamtoBell inj.) or Topotecan in Patients with Recurrent or Refractory Ovarian Cancer